FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David FitzGerald

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Molecular Sequence Data

Physiology

Cell Survival

Anatomy

Genes & Molecular Sequences

Amino Acid Sequences

Co-author Network

Publications

TOP 3
Xiu Fen Liu; David J FitzGerald; Ira Pastan
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.
Abid R Mattoo; David J FitzGerald
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.
Waleed Haso; Daniel W Lee; CRYSTAL MACKALL; Richard A Morgan; Ira H Pastan; Nirali N Shah; Maryalice Stetler-Stevenson; ALAN WAYNE; Constance M Yuan; David M Barrett; Dimiter S Dimitrov; David J FitzGerald; Rimas J Orentas
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David FitzGerald (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Xiu Fen Liu; David J FitzGerald; Ira Pastan
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.
Cancer research 2013;73(7):2281-8.
2013: Abid R Mattoo; David J FitzGerald
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.
International journal of cancer. Journal international du cancer 2013;132(4):978-87.
2013: Waleed Haso; Daniel W Lee; CRYSTAL MACKALL; Richard A Morgan; Ira H Pastan; Nirali N Shah; Maryalice Stetler-Stevenson; ALAN WAYNE; Constance M Yuan; David M Barrett; Dimiter S Dimitrov; David J FitzGerald; Rimas J Orentas
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood 2013;121(7):1165-74.
2012: Hui Wei; Laiman Xiang; ALAN WAYNE; Tapan K Bera; Oleg Chertov; David J FitzGerald; Ira Pastan
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(18):6898-903.
2011: David J FitzGerald; Robert J Kreitman; ALAN WAYNE; Ira Pastan
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
Cancer research 2011;71(20):6300-9.
2011: David J FitzGerald; Elizabeth Moskatel; Gal Ben-Josef; Roberta Traini; Tara Tendler; Ashima Sharma; Antonella Antignani; Francis Mussai; ALAN WAYNE; Robert J Kreitman; Ira Pastan
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
Leukemia & lymphoma 2011;52 Suppl 2():79-81.
2010: Roberta Traini; Gal Ben-Josef; Diana V Pastrana; Elizabeth Moskatel; Ashima K Sharma; Antonella Antignani; David J FitzGerald
ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.
Molecular cancer therapeutics 2010;9(7):2007-15.
2010: Xing Du; Richard J Youle; David J FitzGerald; Ira Pastan
Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1.
Molecular and cellular biology 2010;30(14):3444-52.
2010: Robert Sarnovsky; Tara Tendler; Matheusz Makowski; Maureen Kiley; Antonella Antignani; Roberta Traini; Jingli Zhang; Raffit Hassan; David J FitzGerald
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
Cancer immunology, immunotherapy : CII 2010;59(5):737-46.
2009: Robert J Kreitman; Raffit Hassan; David J FitzGerald; Ira Pastan
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5274-9.
2009: John E Weldon; Laiman Xiang; Oleg Chertov; Inger Margulies; Robert J Kreitman; David J FitzGerald; Ira Pastan
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Blood 2009;113(16):3792-800.
2009: Robert Sarnovsky; Jennifer Rea; Matt Makowski; Ralf Hertle; Colleen Kelly; Antonella Antignani; Diana V Pastrana; David J FitzGerald
Proteolytic cleavage of a C-terminal prosequence, leading to autoprocessing at the N Terminus, activates leucine aminopeptidase from Pseudomonas aeruginosa.
The Journal of biological chemistry 2009;284(15):10243-53.
2008: Xing Du; Richard Beers; David J FitzGerald; Ira Pastan
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.
Cancer research 2008;68(15):6300-5.
2008: Diana V Pastrana; Cheol-heui YUN; Marian L McKee; David J FitzGerald
Mammalian cell expression of an active site mutant of Pseudomonas exotoxin disrupts LRP1 maturation.
Journal of biomedical science 2008;15(4):427-39.
2007: Ira Pastan; Raffit Hassan; David J FitzGerald; Robert J Kreitman
Immunotoxin treatment of cancer.
Annual review of medicine 2007;58():221-37.
2006: Masanori Onda; Satoshi Nagata; David J FitzGerald; Richard Beers; Robert J Fisher; James J Vincent; Byungkook Lee; Michihiro Nakamura; Jaulang Hwang; Robert J Kreitman; Raffit Hassan; Ira Pastan
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(12):8822-34.
2006: Ira Pastan; Raffit Hassan; David J FitzGerald; Robert J Kreitman
Immunotoxin therapy of cancer.
Nature reviews. Cancer 2006;6(7):559-65.
2006: Diana V Pastrana; David J FitzGerald
A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxin.
Analytical biochemistry 2006;353(2):266-71.
2005: Diana V Pastrana; Alison J Hanson; Jane Knisely; Guojun Bu; David J FitzGerald
LRP 1 B functions as a receptor for Pseudomonas exotoxin.
Biochimica et biophysica acta 2005;1741(3):234-9.
2004: David J FitzGerald; Robert Kreitman; Wyndham Wilson; David Squires; Ira Pastan
Recombinant immunotoxins for treating cancer.
International journal of medical microbiology : IJMM 2004;293(7-8):577-82.
2002: Randall J Mrsny; Ann L Daugherty; Marian L McKee; David J FitzGerald
Bacterial toxins as tools for mucosal vaccination.
Drug discovery today 2002;7(4):247-58.
2001: R Hertle; Randall J Mrsny; David J FitzGerald
Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein.
Infection and immunity 2001;69(11):6962-9.
2001: Robert J Kreitman; Wyndham H Wilson; K Bergeron; M Raggio; Maryalice Stetler-Stevenson; David J FitzGerald; Ira Pastan
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
The New England journal of medicine 2001;345(4):241-7.
2000: Robert J Kreitman; Inger Margulies; Maryalice Stetler-Stevenson; Qing-Cheng Wang; David J FitzGerald; Ira Pastan
Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1476-87.
2000: AL Daugherty; Marian L McKee; David J FitzGerald; Randall J Mrsny
Epithelial application of Pseudomonas aeruginosa exotoxin A results in a selective targeting to cells in the liver, spleen and lymph node.
Journal of controlled release : official journal of the Controlled Release Society 2000;65(1-2):297-302.
1999: Marian L McKee; David J FitzGerald
Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story.
Biochemistry 1999;38(50):16507-13.
1999: Robert J Kreitman; Qing-Cheng Wang; David J FitzGerald; Ira Pastan
Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
International journal of cancer. Journal international du cancer 1999;81(1):148-55.
1999: Randall J Mrsny; AL Daugherty; CM Fryling; David J FitzGerald
Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses.
Vaccine 1999;17(11-12):1425-33.
1998: David J FitzGerald; CM Fryling; Marian L McKee; JC Vennari; T Wrin; M E Cromwell; AL Daugherty; Randall J Mrsny
Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1.
The Journal of biological chemistry 1998;273(16):9951-8.
1997: E Mansfield; P Amlot; Ira Pastan; David J FitzGerald
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Blood 1997;90(5):2020-6.
1997: E Mansfield; M F Chiron; P Amlot; Ira Pastan; David J FitzGerald
Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells.
Biochemical Society transactions 1997;25(2):709-14.
1996: M F Chiron; M Ogata; David J FitzGerald
Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin.
Molecular microbiology 1996;22(4):769-78.
1996: E Mansfield; Ira Pastan; David J FitzGerald
Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.
Bioconjugate chemistry 1996;7(5):557-63.
1996: Alexey G Zdanovsky; M V Zdanovskaia; Dudley K Strickland; David J FitzGerald
Ligand-toxin hybrids directed to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein exhibit lower toxicity than native Pseudomonas exotoxin.
The Journal of biological chemistry 1996;271(11):6122-8.
1996: M Gu; V M Gordon; David J FitzGerald; Stephen H Leppla
Furin regulates both the activation of Pseudomonas exotoxin A and the Quantity of the toxin receptor expressed on target cells.
Infection and immunity 1996;64(2):524-7.
1995: Ira Pastan; L H Pai; Ulrich Brinkmann; David J FitzGerald
Recombinant toxins: new therapeutic agents for cancer.
Annals of the New York Academy of Sciences 1995;758():345-54.
1995: David J FitzGerald; C M Fryling; A Zdanovsky; C B Saelinger; M Kounnas; Jeffrey A Winkles; Dudley K Strickland; Stephen H Leppla
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein.
The Journal of cell biology 1995;129(6):1533-41.
1994: David J FitzGerald; C M Fryling; A Zdanovsky; C B Saelinger; M Kounnas; Dudley K Strickland; Stephen H Leppla
Selection of Pseudomonas exotoxin-resistant cells with altered expression of alpha 2MR/LRP.
Annals of the New York Academy of Sciences 1994;737():138-44.
1994: M F Chiron; C M Fryling; David J FitzGerald
Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver.
The Journal of biological chemistry 1994;269(27):18167-76.
1994: Robert J Kreitman; P Bailon; V K Chaudhary; David J FitzGerald; Ira Pastan
Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma.
Blood 1994;83(2):426-34.
1993: Alexey G Zdanovsky; M Chiron; Ira Pastan; David J FitzGerald
Mechanism of action of Pseudomonas exotoxin. Identification of a rate-limiting step.
The Journal of biological chemistry 1993;268(29):21791-9.
1993: Qing-Cheng Wang; L H Pai; W Debinski; David J FitzGerald; Ira Pastan
Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin.
Cancer research 1993;53(19):4588-94.
1993: C P Theuer; David J FitzGerald; Ira Pastan
A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer.
The Journal of urology 1993;149(6):1626-32.
1993: Robert J Kreitman; V K Chaudhary; Thomas Waldmann; Barrie Hanchard; Beverley Cranston; David J FitzGerald; Ira Pastan
Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Leukemia 1993;7(4):553-62.
1993: Robert J Kreitman; Janendra Batra; S Seetharam; V K Chaudhary; David J FitzGerald; Ira Pastan
Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.
Bioconjugate chemistry 1993;4(2):112-20.
1993: Robert J Kreitman; H J Hansen; A L Jones; David J FitzGerald; D M Goldenberg; Ira Pastan
Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Cancer research 1993;53(4):819-25.
1993: C P Theuer; Robert J Kreitman; David J FitzGerald; Ira Pastan
Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Cancer research 1993;53(2):340-7.
1992: M Ogata; C M Fryling; Ira Pastan; David J FitzGerald
Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol.
The Journal of biological chemistry 1992;267(35):25396-401.
1992: David J FitzGerald; Ira Pastan
Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.
Biochemical Society transactions 1992;20(4):731-4.
1992: Robert J Kreitman; V K Chaudhary; R W Kozak; David J FitzGerald; T A Waldman; Ira Pastan
Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.
Blood 1992;80(9):2344-52.
1992: Robert J Kreitman; W P Schneider; C Queen; M Tsudo; David J FitzGerald; Thomas Waldmann; Ira Pastan
Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(8):2810-5.
1992: M Z Kounnas; Randal E Morris; M R Thompson; David J FitzGerald; Dudley K Strickland; C B Saelinger
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A.
The Journal of biological chemistry 1992;267(18):12420-3.
1992: L H Pai; Janendra Batra; David J FitzGerald; M C Willingham; Ira Pastan
Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
Cancer research 1992;52(11):3189-93.
1992: T I Prior; David J FitzGerald; Ira Pastan
Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol.
Biochemistry 1992;31(14):3555-9.
1992: Robert J Kreitman; C B Siegall; David J FitzGerald; Joshua Epstein; Bart Barlogie; Ira Pastan
Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma.
Blood 1992;79(7):1775-80.
1992: Ulrich Brinkmann; L H Pai; David J FitzGerald; Ira Pastan
Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(7):3065-9.
1992: Robert J Kreitman; C B Siegall; V K Chaudhary; David J FitzGerald; Ira Pastan
Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin.
Bioconjugate chemistry 1992;3(1):63-8.
1992: Robert J Kreitman; V K Chaudhary; C B Siegall; David J FitzGerald; Ira Pastan
Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor alpha within Pseudomonas exotoxin as a targeting ligand.
Bioconjugate chemistry 1992;3(1):58-62.
1992: Ira Pastan; V Chaudhary; David J FitzGerald
Recombinant toxins as novel therapeutic agents.
Annual review of biochemistry 1992;61():331-54.
1991: V K Chaudhary; David J FitzGerald; Ira Pastan
A proper amino terminus of diphtheria toxin is important for cytotoxicity.
Biochemical and biophysical research communications 1991;180(2):545-51.
1991: Ulrich Brinkmann; L H Pai; David J FitzGerald; M Willingham; Ira Pastan
B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(19):8616-20.
1991: C B Siegall; S Epstein; E Speir; timothy hla; R Forough; Thomas Maciag; David J FitzGerald; Ira Pastan
Cytotoxic activity of chimeric proteins composed of acidic fibroblast growth factor and Pseudomonas exotoxin on a variety of cell types.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1991;5(13):2843-9.
1991: C B Siegall; M Ogata; Ira Pastan; David J FitzGerald
Analysis of sequences in domain II of Pseudomonas exotoxin A which mediate translocation.
Biochemistry 1991;30(29):7154-9.
1991: L H Pai; M G Gallo; David J FitzGerald; Ira Pastan
Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40).
Cancer research 1991;51(11):2808-12.
1991: C B Siegall; Robert J Kreitman; David J FitzGerald; Ira Pastan
Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.
Cancer research 1991;51(11):2831-6.
1991: L H Pai; Janendra Batra; David J FitzGerald; M C Willingham; Ira Pastan
Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(8):3358-62.
1991: Janendra Batra; David J FitzGerald; V K Chaudhary; Ira Pastan
Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).
Molecular and cellular biology 1991;11(4):2200-5.
1991: T I Prior; David J FitzGerald; Ira Pastan
Barnase toxin: a new chimeric toxin composed of pseudomonas exotoxin A and barnase.
Cell 1991;64(5):1017-23.
1991: T I Prior; Lee Helman; David J FitzGerald; Ira Pastan
Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin.
Cancer research 1991;51(1):174-80.
1990: C B Siegall; G Schwab; R P Nordan; David J FitzGerald; Ira Pastan
Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.
Cancer research 1990;50(24):7786-8.
1990: L H Pai; David J FitzGerald; Mark Tepper; B Schacter; G Spitalny; Ira Pastan
Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice.
Cancer research 1990;50(24):7750-3.
1990: V K Chaudhary; M G Gallo; David J FitzGerald; Ira Pastan
A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(23):9491-4.
1990: M Ogata; V K Chaudhary; Ira Pastan; David J FitzGerald
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol.
The Journal of biological chemistry 1990;265(33):20678-85.
1990: Robert J Kreitman; V K Chaudhary; Thomas Waldmann; M C Willingham; David J FitzGerald; Ira Pastan
The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(21):8291-5.
1990: P Ashorn; Bernard Moss; John N Weinstein; V K Chaudhary; David J FitzGerald; Ira Pastan; Edward A Berger
Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(22):8889-93.
1990: R W Kozak; Haya Lorberboum-Galski; L Jones; Raj K Puri; M C Willingham; T Malek; David J FitzGerald; Thomas Waldmann; Ira Pastan
IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(8):2766-71.
1990: C B Siegall; David J FitzGerald; Ira Pastan
Selective killing of tumor cells using EGF or TGF alpha-Pseudomonas exotoxin chimeric molecules.
Seminars in cancer biology 1990;1(5):345-50.
1990: C B Siegall; David J FitzGerald; Ira Pastan
Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels.
The Journal of biological chemistry 1990;265(27):16318-23.
1990: Haya Lorberboum-Galski; R J Garsia; M Gately; P S Brown; R E Clark; Thomas Waldmann; V K Chaudhary; David J FitzGerald; Ira Pastan
IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes.
The Journal of biological chemistry 1990;265(27):16311-7.
1990: C B Siegall; R P Nordan; David J FitzGerald; Ira Pastan
Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells.
Molecular and cellular biology 1990;10(6):2443-7.
1990: V K Chaudhary; Janendra Batra; M G Gallo; M C Willingham; David J FitzGerald; Ira Pastan
A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(3):1066-70.
1990: C B Siegall; David J FitzGerald; Ira Pastan
Selective killing of IL6 receptor bearing myeloma cells using recombinant IL6-Pseudomonas toxin.
Current topics in microbiology and immunology 1990;166():63-9.
1989: Janendra Batra; Y Jinno; V K Chaudhary; T Kondo; M C Willingham; David J FitzGerald; Ira Pastan
Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(21):8545-9.
1989: Robert Pirker; David J FitzGerald; M Raschack; Z Frank; M C Willingham; Ira Pastan
Enhancement of the activity of immunotoxins by analogues of verapamil.
Cancer research 1989;49(17):4791-5.
1989: C B Siegall; V K Chaudhary; David J FitzGerald; Ira Pastan
Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin.
The Journal of biological chemistry 1989;264(24):14256-61.
1989: M Ogata; V K Chaudhary; David J FitzGerald; Ira Pastan
Cytotoxic activity of a recombinant fusion protein between interleukin 4 and Pseudomonas exotoxin.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(11):4215-9.
1989: V K Chaudhary; C Queen; Richard P. Junghans; Thomas Waldmann; David J FitzGerald; Ira Pastan
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.
Nature 1989;339(6223):394-7.
1989: H Lorberboum-Galski; L V Barrett; R L Kirkman; M Ogata; M C Willingham; David J FitzGerald; Ira Pastan
Cardiac allograft survival in mice treated with IL-2-PE40.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(3):1008-12.
1988: Haya Lorberboum-Galski; R W Kozak; Thomas Waldmann; P Bailon; David J FitzGerald; Ira Pastan
Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor.
The Journal of biological chemistry 1988;263(35):18650-6.
1988: C B Siegall; V K Chaudhary; David J FitzGerald; Ira Pastan
Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(24):9738-42.
1988: V K Chaudhary; T Mizukami; Thomas R Fuerst; David J FitzGerald; Bernard Moss; Ira Pastan; Edward A Berger
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.
Nature 1988;335(6188):369-72.
1988: Y Jinno; V K Chaudhary; T Kondo; Sankar Adhya; David J FitzGerald; Ira Pastan
Mutational analysis of domain I of Pseudomonas exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity.
The Journal of biological chemistry 1988;263(26):13203-7.
1988: M G Gallo; V K Chaudhary; David J FitzGerald; M C Willingham; Ira Pastan
Cloning and expression of the H chain V region of antibody OVB3 that reacts with human ovarian cancer.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(3):1034-40.
1988: Robert Pirker; David J FitzGerald; M C Willingham; Ira Pastan
Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines.
Cancer research 1988;48(14):3919-23.
1983: M C Willingham; H T Haigler; David J FitzGerald; M G Gallo; A V Rutherford; Ira Pastan
The morphologic pathway of binding and internalization of epidermal growth factor in cultured cells. Studies on A431, KB, and 3T3 cells, using multiple methods of labelling.
Experimental cell research 1983;146(1):163-75.